ClinConnect ClinConnect Logo
Search / Trial NCT05759780

OCT Vibrography for Biomechanical Properties of Tissues

Launched by MASSACHUSETTS GENERAL HOSPITAL · Feb 26, 2023

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Biomechanics Cornea Skin Gingiva Optical Coherence Tomography Vibrography

ClinConnect Summary

This clinical trial is studying a new tool called OCT Vibrography, which is designed to measure the mechanical properties of human tissues, like the cornea in the eye, skin, and gums. The goal is to see how well this technology works in understanding the health and condition of these tissues without needing invasive procedures.

To participate in the trial, you need to be between 18 and 75 years old and generally healthy. There are specific groups for people with healthy eyes, skin, and gums, as well as a group for those with a mild or moderate eye condition called keratoconus. Participants can expect to undergo some tests using the OCT Vibrography, which is non-invasive and safe. It's important to note that certain health conditions or previous surgeries may prevent someone from joining the study. If you think you might be eligible or are interested in learning more, please reach out!

Gender

ALL

Eligibility criteria

  • Group 1:
  • Inclusion criteria:
  • • Subjects with healthy eyes (age 18 - 75, N = 50)
  • Exclusion criteria:
  • Subjects with history of eye diseases, and previous eye surgeries.
  • Subjects with diabetes, glaucoma family history
  • Subjects allergic to anesthetic eyedrop, especially proparacaine
  • Subjects with severe allergy
  • Subjects who have difficulty biting
  • Subjects who have recurrent corneal erosion
  • Group 2:
  • Inclusion criteria:
  • • Subjects with healthy skin (age 18 - 75, N = 10)
  • Exclusion criteria:
  • • Subjects with open cuts/sores on the skin, skin infection, or any contagious skin condition
  • Group 3:
  • Inclusion criteria:
  • • Subjects with healthy gingiva (age 18 - 75, N = 10)
  • Exclusion criteria:
  • • Subjects with open cuts/sores on the gingiva, gingiva infection, or any contagious gingiva condition
  • Group 4:
  • Inclusion criteria:
  • • Mild or moderate keratoconus subjects (age 18 - 40, N = 20)
  • Exclusion criteria:
  • • Subjects with K-max above 60 diopters (Pentacam imaging) are excluded

About Massachusetts General Hospital

Massachusetts General Hospital (MGH) is a leading academic medical center located in Boston, Massachusetts, renowned for its commitment to advancing medical research and patient care. As a prominent teaching hospital affiliated with Harvard Medical School, MGH plays a pivotal role in clinical trials across a wide range of disciplines, including cardiology, oncology, neurology, and more. The institution is dedicated to fostering innovative research that translates into effective therapies and improved health outcomes. MGH's Clinical Trials Office provides comprehensive support to facilitate the design, implementation, and management of clinical studies, ensuring adherence to the highest ethical standards and regulatory compliance. With a focus on collaboration and patient-centered care, MGH strives to enhance medical knowledge and contribute to the future of healthcare.

Locations

Boston, Massachusetts, United States

Patients applied

0 patients applied

Trial Officials

Seok-Hyun Yun, PhD

Principal Investigator

Massachusetts General Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials